4503 — Astellas Pharma Income Statement

0.000.00%

Last trade - 00:00

HealthcareConservativeLarge CapNeutral

Annual income statement for Astellas Pharma, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.

	2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Yuho	Yuho	Yuho	Yuho	Tanshin
Standards:	IFRS	IFRS	IFRS	IFRS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	1,249,528	1,296,163	1,518,619	1,603,672	1,912,323
Cost of Revenue
Gross Profit	1,003,465	1,043,154	1,230,266	1,311,187	1,563,117
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	1,102,919	1,135,393	1,390,597	1,578,407	1,871,284
Operating Profit	146,609	160,770	128,022	25,265	41,039
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	145,324	156,886	132,361	24,969	31,237
Provision for Income Taxes
Net Income After Taxes	120,590	124,086	98,714	17,045	50,747
Net Income Before Extraordinary Items
Net Income	120,590	124,086	98,714	17,045	50,747
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	120,589	124,086	98,714	17,045	50,555
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	111	95.3	92.8	45.6	27.9
Dividends per Share